Legend Biotech Corporatio... (LEGN)
| Bid | 35.78 |
| Market Cap | 6.95B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | -1.92 |
| PE Ratio (ttm) | -19.72 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 38.22 |
| Volume | 934,252 |
| Avg. Volume (20D) | 1,331,783 |
| Open | 36.97 |
| Previous Close | 36.42 |
| Day's Range | 36.91 - 39.00 |
| 52-Week Range | 30.17 - 70.13 |
| Beta | undefined |
About LEGN
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM), as well as a comparison of the treatment with standard triplet therapy in revlimid-refr...
Analyst Forecast
According to 12 analyst ratings, the average rating for LEGN stock is "Buy." The 12-month stock price forecast is $82, which is an increase of 116.56% from the latest price.
Next Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago · seekingalpha.com
Top 5 Commercial Biotech Buyout Candidates: Legend Biotech (No. 4)Legend Biotech is a commercial-stage biotech company specializing in innovative cell therapies, with a strong pipeline and global R&D presence. LEGN's flagship product, CARVYKTI, has received multiple...
